Suppr超能文献

血浆四氢生物蝶呤及其口服给药后的药代动力学。

Plasma tetrahydrobiopterin and its pharmacokinetic following oral administration.

作者信息

Fiege Betina, Ballhausen Diana, Kierat Lucja, Leimbacher Walter, Goriounov Dimitri, Schircks Bernhard, Thöny Beat, Blau Nenad

机构信息

Division of Clinical Chemistry and Biochemistry, University Children's Hospital, Steinwiesstrasse 75, 8032 Zurich, Switzerland.

出版信息

Mol Genet Metab. 2004 Jan;81(1):45-51. doi: 10.1016/j.ymgme.2003.09.014.

Abstract

Tetrahydrobiopterin (BH(4)) is widely used as a therapeutic agent in patients with BH(4) deficiencies and mild forms of phenylketonuria (PKU) and there is an increasing need for the measurement of its plasma concentrations in patients with cardiovascular disorders. We measured BH(4) and total biopterin in dithioerythritol (DTE) pretreated plasma from four adults after oral administration of BH(4) (2, 10, and 20mg/kg body weight) using the differential iodine oxidation method. About 80% (range 64.8-92.2% ) of total biopterin was found as BH(4) when analyzed immediately after blood sampling. Compared with ascorbic acid as an antioxidant, DTE was more protective against oxidation of BH(4), particularly in samples stored over a period of 8 months. Without antioxidant (DTE or ascorbic acid) almost no BH(4) was detected. Furthermore, BH(4) and total biopterin were measured at different time intervals (up to 33 h after oral administration) and pharmacokinetic parameters T(max) (1-4h), C(max) (258.7-259.0 nmol/L biopterin at a dosage of 10mg/kg), and area under the curve (AUC=1708-1958 nmol(*)h/L up to T=10h) were estimated. The elimination half-life time was calculated to be 3.3-5.1h. Doubling the BH(4) dosage to 20mg/kg resulted in 60% higher AUC while sublingual BH(4) application (2mg/kg) resulted in 58-76% higher BH(4) plasma concentrations when compared with oral administration. These preliminary data suggest that in patients with BH(4) cofactor defects and BH(4)-responsive phenylalanine hydroxylase deficiency, BH(4) should be given in at least two to three daily doses and that sublingual administration may lower the required BH(4) dosage and subsequently the cost of treatment. Due to inter individual differences in pharmacokinetic properties, in some patients with hyperphenylalaninemia and mild PKU plasma BH(4) levels may be not high enough to fully activate the liver phenylalanine hydroxylase and thus lower blood phenylalanine levels. Assessment of plasma BH(4) or total biopterin concentrations may be a good way to control the efficacy of the loading test.

摘要

四氢生物蝶呤(BH(4))被广泛用作治疗BH(4)缺乏症和轻度苯丙酮尿症(PKU)患者的药物,心血管疾病患者对其血浆浓度测定的需求也日益增加。我们采用差示碘氧化法,测定了4名成年人在口服BH(4)(2、10和20mg/kg体重)后,经二硫苏糖醇(DTE)预处理的血浆中的BH(4)和总生物蝶呤。采血后立即分析发现,总生物蝶呤中约80%(范围为64.8 - 92.2%)为BH(4)。与作为抗氧化剂的抗坏血酸相比,DTE对BH(4)的氧化具有更强的保护作用,尤其是在储存8个月的样本中。在没有抗氧化剂(DTE或抗坏血酸)的情况下,几乎检测不到BH(4)。此外,在不同时间间隔(口服后长达33小时)测定了BH(4)和总生物蝶呤,并估算了药代动力学参数T(max)(1 - 4小时)、C(max)(10mg/kg剂量时为258.7 - 259.0 nmol/L生物蝶呤)和曲线下面积(AUC = 1708 - 1958 nmol(*)h/L直至T = 10小时)。消除半衰期经计算为3.3 - 5.1小时。将BH(4)剂量加倍至20mg/kg导致AUC升高60%,而与口服给药相比,舌下含服BH(4)(2mg/kg)导致BH(4)血浆浓度升高58 - 76%。这些初步数据表明,对于BH(4)辅因子缺陷和BH(4)反应性苯丙氨酸羟化酶缺乏的患者,BH(4)应至少每日分两至三次给药,舌下给药可能会降低所需的BH(4)剂量,从而降低治疗成本。由于药代动力学特性存在个体差异,在一些高苯丙氨酸血症和轻度PKU患者中,血浆BH(4)水平可能不足以充分激活肝脏苯丙氨酸羟化酶,从而无法降低血液苯丙氨酸水平。评估血浆BH(4)或总生物蝶呤浓度可能是控制负荷试验疗效的一种好方法。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验